Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.72 EUR | -1.85% | +0.54% | +17.72% |
May. 23 | FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors | |
Apr. 26 | FAES FARMA : Q1 beat; full-year guidance re-affirmed |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is in a robust financial situation considering its net cash and margin position.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.72% | 1.28B | B | ||
+42.83% | 748B | C+ | ||
+34.11% | 598B | B | ||
-5.70% | 356B | C+ | ||
+18.06% | 325B | B- | ||
+4.63% | 283B | C+ | ||
+17.02% | 245B | B+ | ||
+9.26% | 211B | B- | ||
-4.21% | 209B | A+ | ||
+2.43% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FAE Stock
- Ratings Faes Farma, S.A.